Loading organizations...
§ Private Profile · Errol Road, Invergowrie, Dundee, Scotland, DD2 5DA
Outrun TX is a technology company.
Outrun Therapeutics is a preclinical biotechnology company developing novel treatments through protein stabilization. It employs an innovative E3 ligase inhibition approach, preventing crucial protein degradation. The company uses a proprietary platform for small molecule inhibitors targeting specific E3 ligases, stabilizing beneficial proteins like tumor suppressors. Their lead program addresses HPV positive head and neck cancer.
Founded by Prof. Satpal Virdee, Dr. Mathew Stanley, and Dr. Kuan-Chuan Pao, the company emerged from Professor Virdee’s lab at the MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee. This origin was driven by the insight that modulating E3 ligases offers a new therapeutic modality through targeted protein stabilization.
Outrun Therapeutics aims to develop therapies for patients with diseases like cancer, where selective protein stabilization offers significant benefits. Its vision empowers the body’s intrinsic mechanisms to fight illness. By fully leveraging protein stabilization’s potential, Outrun Therapeutics seeks to improve patient outcomes and advance treatment strategies.
Outrun TX has raised $10.0M across 1 funding round.
Outrun TX has raised $10.0M in total across 1 funding round.
Outrun TX has raised $10.0M in total across 1 funding round.
Outrun TX's investors include Brandon Capital Partners, EQT Life Sciences, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Polaris Partners, Sanofi Ventures, Bauke Anninga.
Outrun TX has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $10M Seed | — | Brandon Capital Partners, EQT Life Sciences, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Polaris Partners, Sanofi Ventures, Bauke Anninga | Announced |
Outrun Therapeutics (Outrun TX) is a preclinical biotechnology company developing small molecule inhibitors that target E3 ligases to stabilize tumor suppressor proteins, primarily for treating hard-to-treat solid tumors and other diseases.[1][2][4] Founded in 2019 as a spin-out from the University of Dundee, it serves the biotech and pharmaceutical sectors by advancing a proprietary platform that has generated a lead program in oncology, supported by $10M in seed funding raised in May 2024 from M Ventures and MP Healthcare Venture Management.[1][2][3][4] The company's scalable approach addresses protein destabilization in cancer, marking early growth momentum through platform validation and investor backing.[1][4]
Outrun Therapeutics emerged in 2019 from Prof. Satpal Virdee’s lab at the University of Dundee’s MRC Protein Phosphorylation and Ubiquitylation Unit, a hub for ubiquitin system research.[2][3][4] Key founders include Principal Scientist Mathew (DPhil in Organic Chemistry from University of Sussex, with expertise in small molecule drug discovery), Dr. Kuan-Chuan Pao (PhD from MRC-PPU, postdoc at UC Berkeley, experienced in chemical and cell biology), and the broader team led by CEO Dr. Carolyn Porter.[3] The idea stemmed from deep insights into E3 ligase biology, leading to a proprietary platform for inhibitor discovery; early traction came via rapid pipeline construction, culminating in the $10M seed round in May 2024 to advance preclinical programs.[1][2][4]
Outrun rides the wave of targeted protein modulation in biotech, shifting from degradation (e.g., PROTACs) to stabilization via E3 ligase inhibition—a nascent field unlocking undruggable targets in oncology.[2][4] Timing aligns with surging demand for precision therapies in solid tumors, fueled by advances in ubiquitin biology and AI-driven drug discovery, amid a biotech funding rebound post-2023 downturn.[1][4] Market forces like aging populations and unmet needs in hard-to-treat cancers favor its platform, while its Dundee origins bolster the UK’s life sciences ecosystem, influencing pipeline diversification beyond oncology.[2][3]
Outrun’s near-term path involves advancing its lead E3 inhibitor into IND-enabling studies, leveraging $10M to expand the pipeline across diseases.[1][4] Trends like multi-modal protein therapies and ligase-focused PROTACs will accelerate validation, potentially drawing Big Pharma partnerships. Its influence may grow by pioneering stabilization modalities, evolving from preclinical innovator to a platform-licensing leader in oncology biotech. This positions Outrun TX as a high-potential bet on next-gen small molecules transforming cancer treatment.[2][4]